Kos gets GMP warning letter on Niaspan, Advicor
Kos is submitting a corrective action plan to FDA following a warning letter on Niaspan and Advicor good manufacturing practices violations. The Dec. 29 1warning letter follows an inspection at Kos' Edison, N.J., facility in July and August 2003. FDA cites failures to properly investigate dissolution and content uniformity failures and notes that similar problems were observed during an April 2002 inspection...
You may also be interested in...
The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.
Inovio Pharmaceuticals has reported promising initial data from its first Phase III study of its electrical current-driven DNA plasmid-based immunotherapy, VGX-3100, in virus-associated cervical dysplasia; it is heading a small group of companies evaluating novel therapies in the condition, which often advances to cancer.
In the month ahead, a key ANDA approval could come for Viatris, while additional competition to Gilead Sciences’ Truvada for PrEP is on the way in the US following Teva and Amneal’s launches.